Year/Cases | Diagnoses | Age RA | Age VAS | Vasculitis symptoms | Positive antibodies | RA therapy | Follow-up |
---|---|---|---|---|---|---|---|
1974/1 (Pritchard 1976) | RA/GPA | 40 | 59 | ENT | RhF, ANA | Gold, tuberculin injections, NSAID | D |
1976/2 (Ohashi et al. 1992) | RA/GPA | 45 | 45 | ENT | RhF | HCQ, aspirin | I |
RA/GPA | 73 | 75 | ENT, Eyes, Lung | RhF | Gold, NSAID | I | |
11992/1 (Steuer et al. 1995) | RA/GPA | 33 | 38 | ENT | RhF | NSAID, Gold | I |
1995/1 (Harper et al. 1997) | RA/MPA | 49 | 62 | Lung,Kidney | RhF, ANA, p-ANCA | NSAID, Gold, SFZ | I |
1997/10 (Messiaen et al. 1998) | RA/MPA | 31-62 | NA | 5: kidney only | 4: p-ANCA | 6: NSAID | 4 D |
1: kidney, lung, eye | 9: RhF | 1: NSAID, Penicillamine HCQ | 2 HD | ||||
3: kidney, skin | 6: ANA | 1: Prednisone, SFZ, Gold | 4 I | ||||
1:kidney, bowel, skin | 1: HCQ | ||||||
1: HCQ, SFZ | |||||||
1999/1 (Yorioka et al. 1999) | RA/MPA | 22 | 24 | Kidney | RhF, ANA, MPO-ANCA | NSAID | I |
2002/2 (Chinoy & McKenna 2002) | RA/GPA | 32 | 32 | ENT, Lung, Kidney | p-ANCA | Prednisolone, NSAID, CYC | I |
RA/GPA | *41 | 26 | Lung | p-ANCA | I | ||
2003/2 (Douglas et al. 2003) | RA/GPA | 36 | 37 | ORL, Lung, Kidney | RhF, PR3-ANCA | Prednisolone, MTX, NSAID. | I |
RA/GPA | 35 | 55 | Lung | RhF, PR3-ANCA | NSAID, MTX | I | |
2005/1 (Goto et al. 2005) | RA/MPA | 44 | 48 | ORL, eyes, Kidney | MPO-ANCA, RhF, ANA | MTX, Penicillamine, Gold, prednisolone | I |
2008/1 (Pai & Panda 2008) | RA/GPA | 57 | 60 | Lung | RhF, Anti-CCP, PR3-ANCA | HCQ, prednisolone | I |
2012/4 (Szilasi et al. 2012) | RA/GPA | 40 | 70 | Lung, Kidney | PR3-ANCA, Anti-CCP,RhF | Prednisolone | I |
RA/MPA | *49 | 44 | Lung, Kidney | MPO-ANCA, RhF | Adalimumab, RTX | I | |
RA/MPA | 28 | 34 | Lung, Kidney | MPO-ANCA, RhF | Prednisone, SFZ, MTX | I | |
RA/EGPA | 52 | 54 | Skin | MPO-ANCA, RhF | MTX, Cyclosporine | I | |
2012/1 (Vaishnav et al. 2012) | RA/GPA | 36 | 37 | Lung | c-ANCA, RhF | D | |
2013/1 (Reitblat & Reitblat 2013) | RA/GPA | 45 | 58 | Kidney | PR3-ANCA, RhF | MTX, Etanercept | HD |
2014/1 (Ortiz-Sierra et al. 2014) | RA/GPA | 65 | 67 | Skin, lung, ENT, eye | RhF, c-ANCA | MTX, Prednisone, etanercept, | I |
Our report | 5 RA/MPA | 24-63 | 63-69 | 1: Kidney, lung | 3: RhF | 1: MTX, prednisone | 5 I |
1 RA/GPA | 5: Kidney | 1: Anti-CCP | 1: SFZ | 1 HD | |||
1: PR3-ANCA | 1: HCQ, MTX, leflunomide | 1D | |||||
3: MPO-ANCA | 1: Infliximab, MTX, SFZ | ||||||
1: Etanercept, MTX, SFZ, AZA | |||||||
1: Prednisolone |